Exposure to environmental endocrine disruptors is a potential risk factor for humans. With the increasing use of ultraviolet (UV) filters in sunscreens and cosmetics and as additives in plastics and household products, their possible environmental impact deserves consideration. UV filters may be directly introduced into surface waters during swimming or they may enter wastewater from households or industry. There is good evidence that pharmaceuticals and ingredients of personal care products can spread into the biosphere and reach the food chain: UV filters are present in water downstream of sewage treatment plants ([@b14-ehp0116-000867]; [@b20-ehp0116-000867]) in surface waters ([@b3-ehp0116-000867], [@b2-ehp0116-000867]), and they bioaccumulate in fish ([@b1-ehp0116-000867], [@b2-ehp0116-000867]; [@b19-ehp0116-000867]). In a recent monitoring study, UV filters were found in 75% of human milk samples ([@b30-ehp0116-000867]), indicating potential exposure of newborns.

Certain UV filters have been shown to exhibit estrogenic activity in both *in vitro* and *in vivo* assays ([@b29-ehp0116-000867], [@b31-ehp0116-000867]), and they have also shown developmental toxicity ([@b6-ehp0116-000867], [@b5-ehp0116-000867]; [@b16-ehp0116-000867]). *In vitro* studies showed that 4-methyl-benzylidene camphor (4-MBC) and 3-benzylidene camphor (3-BC), are estrogen receptor (ER)-β ligands ([@b31-ehp0116-000867]), but they are also active in ER-α--typical *in vivo* tests such as the uterotrophic assay ([@b29-ehp0116-000867], [@b31-ehp0116-000867]).

Many endocrine-active xenobiotics affect normal cellular and developmental processes in animal models, with the prostate being one sensitive target ([@b39-ehp0116-000867]; [@b45-ehp0116-000867]). These effects can be seen in both the juvenile and adult stages of growth in the prostate. Developmental exposure to 4-MBC and 3-BC affects prostate weight and estrogen target gene expression, in addition to effects on other targets such as brain, uterus, and thyroid ([@b6-ehp0116-000867], [@b5-ehp0116-000867]; [@b16-ehp0116-000867]; [@b32-ehp0116-000867]).

Although fetal prostate development is primarily regulated by androgens ([@b36-ehp0116-000867]), addition of exogenous estrogens during critical periods of growth has the potential to alter the development of the prostate ([@b24-ehp0116-000867]; [@b39-ehp0116-000867]; [@b45-ehp0116-000867]). Growth responses to estrogen and estrogen mimics are variable and depend on dose and timing of treatment. Low-level exposure to estrogenic compounds administered during fetal development results in a region-specific proliferative growth response ([@b39-ehp0116-000867]; [@b45-ehp0116-000867]). Conversely, postnatal treatment with higher doses of estrogen has an inhibitory effect on growth ([@b13-ehp0116-000867]; [@b23-ehp0116-000867]; [@b39-ehp0116-000867]).

In the present study we investigated the effects of 4-MBC and 3-BC on the developing prostate in the fetal rat. This experiment was designed, as previously described ([@b6-ehp0116-000867], [@b5-ehp0116-000867]; [@b16-ehp0116-000867]), to examine the effects caused by systemic, low-dose exposure throughout *in utero* development. We administered 4-MBC and 3-BC at two dose levels, corresponding to previously published classical lowest observed adverse effect level (LOAEL) and classical no observed adverse effect level (NOAEL)/molecular LOAEL, respectively ([@b6-ehp0116-000867], [@b5-ehp0116-000867]; [@b16-ehp0116-000867]; [@b30-ehp0116-000867]). Our data support the hypothesis that exposure to low doses of environmentally relevant endocrine disruptors during early prostate development alters normal growth patterns and extends the range of active chemicals to UV filters used in cosmetics.

Materials and Methods
=====================

Chemicals
---------

We purchased 4-MBC (Eusolex 6300, CAS no. 36861-47-9, molecular weight 254.37, purity 99.7--99.9%) from Merck Schweiz (Dietikon, Switzerland) and 3-BC (Unisol-S22, CAS no. 15087--24--8, molecular weight 240.0, purity \> 97.0 %) from Induchem AG (Volketswil, Switzerland).

Animals
-------

Long Evans rats were purchased from Centre d'Elevage R. Janvier (Le Genest-St. Isle, France) and shipped to the animal facility of the Department of Physiology, Medical School, Complutense University, Madrid, Spain. The animals were kept under controlled conditions with free access to water and a soy-free rat chow (Nutreco, Toledo, Spain). Animal experiments followed the European Union normative (86/609/EEC; [@b7-ehp0116-000867]) and were approved by the Institutional Animal Care Committee of Complutense University. All animals were treated humanely and with regard for alleviation of suffering.

4-MBC or 3-BC treatment
-----------------------

Chow was prepared by adding 4-MBC and 3-BC to the soy-free rat chow (Nutreco). 4-MBC was added at concentrations of 10 and 100 mg/kg chow, yielding an average daily intake of 0.7 and 7 mg/kg body weight (bw)/day, and 3-BC was added at concentrations of 1 and 3.3 mg/kg chow, yielding a dose of 0.07 and 0.24 mg/kg bw/day. Control chow consisted of the same matrix.

This study was part of a larger study involving dissection of brain and reproductive organs at different postnatal stages and was designed to mimic exposure through the food chain during prenatal and early postnatal life. Males and females of the parent generation (F~0~; 5--6 weeks of age) were fed for at least 10 weeks before mating (including one spermatogenic cycle) with chow containing 4-MBC (0.7 or 7 mg/kg bw/day) or 3-BC (0.07 or 0.24 mg/kg bw/day) or control chow. Treatment continued throughout pregnancy and lactation. Rats were allowed to mate overnight, and pregnant (sperm-positive) females were kept in groups of two and separated 1 day before parturition.

Birth and tissue preparation
----------------------------

Around expected birth term \[gestational day (GD) 23; GD1 = 24 hr after mating\], we observed pregnant dams at least three times during the light period for signs of birth. The day of birth was defined as postnatal day (PND) 1 (GD23). The dam and litter remained undisturbed until all the offspring had been born. Then one or two of the male offspring were gently taken out of the cage, wrapped in warm paper towels, and kept under red light (32 ± 1°C) for 1--2 min before being anesthetized by cooling the body until motionlessness in crushed ice. After decapitating the rats on a precooled plate (ice), the lower part of the body was sectioned just below the level of the umbilical cord using a razor blade and immediately immersed into 4% buffered formaldehyde for 24 hr and stored in 70% ethanol. One offspring per litter was transferred to the University of South Dakota for final tissue preparation, three-dimensional (3-D) reconstruction, and morphometric analysis.

3-D reconstruction
------------------

The urogenital sinus (UGS) and developing prostate were processed as described previously ([@b39-ehp0116-000867]). Briefly, serial tissue sections (6 μm) were stained with hematoxylin and eosin and photographed with an Olympus DP70 digital camera fitted to an Olympus BX60 microscope (Leeds Precision Instruments, Minneapolis, MN, USA). Histological images of the developing prostate buds and associated structures were traced, contoured, and realigned as surface-rendered 3-D models using Winsurf reconstruction software (University of Hawaii at Manoa, Honolulu, HI, USA). To compare and examine the effects of the treatments with untreated control animals, we performed morphometric and volumetric analyses.

Statistics
----------

All volumetric and ductal development data, with the exception of the mesenchymal study, were analyzed using one-way analysis of variance, followed by a Dunnett's post hoc test, using StatMost for Windows software (DataMost Corporation, Salt Lake City, UT, USA). We analyzed the mesenchyme volume data using the Mann-Whitney test. The confidence level for rejecting the null hypothesis was *p* \< 0.05. Data are presented as mean ± SE. For all groups, *n* = 4. All samples were blinded to ensure the absence of bias.

Results
=======

Accessory sex glands
--------------------

[Figure 1A](#f1-ehp0116-000867){ref-type="fig"} illustrates the components of the accessory sex glands (ASGs) that were examined individually or as anatomically related groups. The ASGs, including the seminal vesicles (SV), coagulating gland (CG), and the dorsal, lateral, and ventral prostate (DLVP) as a whole, were significantly sensitive to the effects of 4-MBC at the 7.0-mg/kg bw dose ([Figure 2](#f2-ehp0116-000867){ref-type="fig"}). All of the subsequent findings pertain to the effects of exposure to this dose of 4-MBC compared with untreated control males. No significant effects were observed under any 3-BC treatments or the 0.7-mg/kg bw dose of 4-MBC.

We observed a 69% overall increase in the ASG volume (*p* \< 0.005), compared with untreated controls. Treatment significantly increased the volume of the SV by 66% (*p* \< 0.001), the CG by 68% (*p* \< 0.01), and the developing prostate (DLVP) by 69% (*p* \< 0.01; [Figure 2](#f2-ehp0116-000867){ref-type="fig"}). We also observed a narrowing of the urethra at the neck of the bladder in this treatment group ([Figure 1F](#f1-ehp0116-000867){ref-type="fig"}). This feature is consistent with a prior study of endocrine disruptor exposure ([@b39-ehp0116-000867]).

Dorsolateral prostate
---------------------

A detailed 3-D reconstruction of a specific group of ducts in the developing dorsolateral prostate revealed that the most sensitive region to 4-MBC was the caudal area of dorsal prostatic ducts, which increased in volume by 62% (*p* \< 0.05; [Figures 1A,C](#f1-ehp0116-000867){ref-type="fig"} and [2](#f2-ehp0116-000867){ref-type="fig"}). In contrast, the cranial portion of the dorsal prostate and the lateral prostate did not exhibit any significant growth response to treatment.

Ventral prostate and ventral mesenchymal pad (VMP)
--------------------------------------------------

We observed a significant increase in prostatic duct volume (106%; *p* \< 0.01) in the ventral region of the prostate ([Figure 3](#f3-ehp0116-000867){ref-type="fig"}). The 3-D reconstruction analysis also revealed a more pronounced development of distal tip branching morphogenesis ([Figure 1B,C,D](#f1-ehp0116-000867){ref-type="fig"}). The VMP ([@b41-ehp0116-000867]), which is intimately involved in distal tip branching, was also increased in volume by 64% (*p* \< 0.05; [Figure 1F](#f1-ehp0116-000867){ref-type="fig"}).

Prostatic duct development
--------------------------

The number of prostate ducts developing from the UGS has been shown to increase after prenatal estrogen treatment ([@b39-ehp0116-000867]; [@b45-ehp0116-000867]). In the present study we observed a similar increase in the number of dorsal ducts, particularly in the caudal region of the UGS (62%, *p* \< 0.05; [Figure 4](#f4-ehp0116-000867){ref-type="fig"}). However, despite an increased ductal volume in the ventral prostate, there was no increase in the number of ducts growing from the ventral wall of the UGS ([Figures 1C](#f1-ehp0116-000867){ref-type="fig"} and [4](#f4-ehp0116-000867){ref-type="fig"}).

Discussion
==========

Normal prostate development is dependent on androgens ([@b36-ehp0116-000867]). However, exposure to abnormally high levels of estrogen during the critical period of development has the potential to alter growth-control mechanisms ([@b12-ehp0116-000867]; [@b22-ehp0116-000867]). In contrast, low-level exposure to estrogen, or estrogen mimics, during the same developmental period has been shown to alter the regulation of androgen receptors (AR) and ERs ([@b24-ehp0116-000867]; vom [@b45-ehp0116-000867]). A shift in receptor density predisposes the prostate for altered hormonal regulation ([@b46-ehp0116-000867]). Along with changes in receptor regulation, endocrine-disrupting compounds inhibit the production of phosphodiesterase and increase transcription of the aromatase gene *CYP19* (cytochrome P450) under promotion of aromatase promoter II in the prostate ([@b8-ehp0116-000867]). This aromatization of testosterone into localized free estrogen can further destabilize the androgen-regulated growth of prostatic epithelium.

The results of the present study support the classification of 4-MBC as an endocrine disruptor ([@b29-ehp0116-000867], [@b32-ehp0116-000867]; [@b33-ehp0116-000867]). The doses of 7 and 0.7 mg/kg bw/day examined in this study represent the LOAEL and NOAEL, respectively, for classical toxicity end points in extended one generation--type studies, such as puberty in males, adult ventral prostate weight, and female sexual behavior. Changes in estrogen-regulated gene expression in adult male and female offspring were still present at the lower dose, 0.7 mg/kg bw/day ([@b6-ehp0116-000867], [@b5-ehp0116-000867]; [@b16-ehp0116-000867]; [@b30-ehp0116-000867]). In chronic (90-day) studies on adult ovariectomized rats, interactions of 4-MBC with estrogenic mechanisms have been observed in additional targets such as luteinizing hormone, bone, adipose tissue, and leptin. However, these effects were seen at higher doses than those used in our developmental toxicity studies ([@b34-ehp0116-000867], [@b35-ehp0116-000867]).

Exposure of neonates to the chemicals has been assessed by determining 4-MBC and 3-BC concentrations in rat milk ([@b30-ehp0116-000867]). The effective dose of 7 mg/kg bw/day yields a 4-MBC concentration of 209 ng/g lipid, which is 11 times the highest value found thus far in our ongoing monitoring study on human milk (19 ng/g lipid). This level would be considered within the risk factor zone for human safety.

The prostate is very sensitive to deviations from homeostatic androgen-to-estrogen ratios. Compounds that mimic the effects of estrogen have the potential to alter the development of the prostate by inducing morphologic changes ([@b21-ehp0116-000867]; [@b39-ehp0116-000867]; [@b45-ehp0116-000867]). These effects follow an inverted U-curve pattern, which at low doses cause a proliferative response ([@b39-ehp0116-000867]) and at higher doses cause an inhibitory effect (vom [@b45-ehp0116-000867]). In the present study, using low-dose *in utero* systemic exposure, we observed proliferative effects similar to those found in other low-dose exposure experiments ([@b39-ehp0116-000867]; [@b45-ehp0116-000867]).

4-MBC is a preferential ER-β ligand with limited ER-α binding capacity *in vitro* ([@b18-ehp0116-000867]; [@b31-ehp0116-000867]), but it also exerts estrogenic effects *in vivo* that depend on ER-α, such as the uterotrophic response in immature rats ([@b29-ehp0116-000867], [@b31-ehp0116-000867]). This might be due to an estrogenic metabolite whose activity has not been characterized in detail ([@b44-ehp0116-000867]). Thus, *in vivo* effects of this UV filter probably represent a combination of ER-β-- and ER-α--mediated actions. Reporter gene assays on AR yielded conflicting results for both 4-MBC and 3-BC, including complete absence of agonistic or antagonistic activity, in contrast to some other UV filters ([@b15-ehp0116-000867]), as well as the presence of weak antiandrogenic activity ([@b33-ehp0116-000867]). So far, interactions with androgenic mechanisms have not been tested in acute *in vivo* models, but estrogenic activity of 4-MBC and 3-BC has been confirmed in the uterotrophic assay ([@b29-ehp0116-000867], [@b31-ehp0116-000867]; [@b43-ehp0116-000867]). Thus, actions on ER seem to provide the most straightforward explanation for the effects of 4-MBC on the neonatal prostate. It is interesting that the dose of 7 mg/kg bw/day 4-MBC enhances prostate growth during the neonatal period but causes a decrease in the weight of ventral and dorsolateral prostate lobes and a reduced expression of AR and ER-α at mRNA and protein levels in chronically exposed adult offspring ([@b5-ehp0116-000867]; [@b30-ehp0116-000867]). Because the adult rats had been continuously exposed during prenatal and postnatal life, it seems possible that the different effects are due to a switch in the relative importance of the actions on ER-α and ER-β. The consequences of this switch, with regard to potential lifelong exposure, should be kept in mind ([@b5-ehp0116-000867]; [@b30-ehp0116-000867]).

The lack of effect of 3-BC was surprising because 3-BC and 4-MBC behave very similarly in acute tests for estrogenic activity ([@b29-ehp0116-000867], [@b31-ehp0116-000867]). The 3-BC doses we used affect gene expression in the early post-natal uterus ([@b30-ehp0116-000867]), but they may be too low to influence prostate growth. However, in spite of similarities in chemical structure and acute actions, the effect patterns of 4-MBC and 3-BC differ in developmentally exposed adult animals ([@b5-ehp0116-000867]; [@b30-ehp0116-000867]). Ventral prostate weight was reduced by 4-MBC in a dose-dependent manner, but it was unaffected by 3-BC except for the lowest dose used in that study (0.24 mg/kg bw/day). Also, effects of 3-BC and 4-MBC on AR and ER-α in prostate of adult offspring were opposite at mRNA and protein levels ([@b5-ehp0116-000867]; [@b30-ehp0116-000867]). Thus, it seems conceivable that effects of two compounds on the neonatal prostate may differ, even though the reason for this difference remains unknown.

The different growth effects within specific regions of the prostate substantiate earlier studies. Previously, the combined dorsal and lateral regions were grouped as the dorsolateral prostate ([@b23-ehp0116-000867]; [@b39-ehp0116-000867]). Using our 3-D reconstruction program, Winsurf, we were able to further differentiate the dorsolateral prostate into its dorsal and lateral components. In addition, the dorsal prostate was divided into two distinct regions separate from the lateral prostate ([Figure 1A](#f1-ehp0116-000867){ref-type="fig"}). The effects seen in these areas were unique. We observed no significant volumetric changes in the lateral prostate or in the cranial region of the dorsal prostate ducts ([@b41-ehp0116-000867]), a region described as LP1 by [@b11-ehp0116-000867]. In the caudal region of the dorsal prostate ducts there was a significant increase in volume, which was primarily due to an increase in the number of ducts developing from the UGS wall ([Figure 1C](#f1-ehp0116-000867){ref-type="fig"}). In the normal rodent prostate the number of ducts that develop from the wall of the UGS is fairly constant ([@b39-ehp0116-000867]). Any additional ducts formed then become part of the adult glandular structure and have the potential to increase the prevalence of disorders later in life ([@b25-ehp0116-000867]).

An important component of ductal formation is the surrounding mesenchymal tissue into which the prostatic buds grow ([@b4-ehp0116-000867]). Growth factors produced by this tissue play an important role in the process of branching morphogenesis and early glandular development ([@b38-ehp0116-000867]). Each region of the prostate and the adjacent Wolffian duct system contain their own respective mesenchyme ([@b10-ehp0116-000867]; [@b38-ehp0116-000867]; [@b41-ehp0116-000867], [@b40-ehp0116-000867], [@b42-ehp0116-000867]). Branching morphogenesis is initiated after the buds grow into their local mesenchyme ([@b40-ehp0116-000867]; [@b45-ehp0116-000867]). Branching morphogenesis is the process by which the distal tips of immature prostatic ducts begin bifurcation and form the complex glandular architecture commonly seen in the adult prostate ([Figure 1D](#f1-ehp0116-000867){ref-type="fig"}). The increased ductal volume in the ventral prostate that resulted from an increase in the distal tip volume was a very different response to that seen in the dorsal ducts, where the increased ductal volume was primarily due to an increase in the number of ducts. These distinct regional differences suggest that exposure to endocrine disruptors during fetal development can affect specific developmental events, such as duct formation and branching morphogenesis. Furthermore, this suggests that environmental estrogens can exert their effects on distinct mechanisms within the same tissue. Because the VMP ([@b41-ehp0116-000867]) is an important growth-inducing tissue in ventral prostate development ([@b38-ehp0116-000867]), we examined the volumetric parameter and found a significant increase in volume after 4-MBC exposure ([Figures 1E](#f1-ehp0116-000867){ref-type="fig"} and [5](#f5-ehp0116-000867){ref-type="fig"}). The VMP is present before the onset of ductal outgrowth ([@b41-ehp0116-000867], [@b40-ehp0116-000867]), and it is possible that the increased volume may have been established before ductal development in response to 4-MBC exposure. The increase in the number of caudal ducts in the dorsal prostate may reflect a growth effect of exposure via epithelial--mesenchymal interactions in the peri-urethral mesenchyme surrounding the urothelium. This mesenchyme is distinct from the VMP ([@b40-ehp0116-000867]) and is likely to express different growth factors.

The recent evidence regarding the effects of 4-MBC on the developing fetus has placed this widely used UV filter in the category of known endocrine-disrupting compounds ([@b30-ehp0116-000867]; [@b37-ehp0116-000867]). The effects of this compound on the developing prostate are strikingly similar to those of another known estrogen-mimicking compound, bisphenol A (BPA; [@b39-ehp0116-000867]). UV filters, including 4-MBC, bio-accumulate in the environment ([@b1-ehp0116-000867]; [@b2-ehp0116-000867]). They were found in 75% of human milk samples ([@b30-ehp0116-000867]), indicating potential transfer of these chemicals to the newborn infant. Human exposure stems mainly from the use of cosmetics, but exposure may also originate from the food chain. Both the European Union \[[@b27-ehp0116-000867], [@b28-ehp0116-000867]\] and the U.S. [@b9-ehp0116-000867] are currently reviewing data on 4-MBC, also known as enzacamene, Parsol 5000 ([@b26-ehp0116-000867]), and Eusolex 6300 ([@b17-ehp0116-000867]). The different responses observed in the present study suggest that the two developmental processes of ductal outgrowth and branching morphogenesis are affected independently by exposure to environmental chemicals at critical periods of UGS development. Our findings of prenatal growth effects, plus previous reports that these compounds are found in the environment, justify additional studies to determine the mechanisms underlying the characteristic growth responses during fetal development.
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![3-D serial section reconstruction of accessory reproductive organs in male PND1 Long Evans rats after systemic and developmental *in utero* exposure to 7.0 mg/kg bw 4-MBC. Abbreviations: DT, distal tip; PD, proximal duct, VMP, ventral mesenchymal pad. (*A*) Right lateral view of the surface-rendered anatomical reconstruction of the UGS and ASG structures in a control male. Individual structures are identified by color. (*B*) Reconstruction of the right lateral and cranial views of the UGS from a 4-MBC--treated male and untreated control male illustrating the significant regional growth differences in ducts of the caudal dorsal prostate and branching morphogenesis development in the ventral region. (*C*) Additional anatomical views of the prostatic ducts of a control male and a 4-MBC treated male showing the regional growth patterns. (*D*) Representative histological views of distal-tip budding in the ventral prostate region. Initial bifurcation is the primary feature of the control male, whereas extensive secondary branching morphogenesis has occurred in the 4-MBC--treated male (stained with hematoxylin and eosin; bar = 100 μm). (*E*) Anatomical view of the UGS, ventral ducts, and VMP showing that the distal tips of the ducts in the control male have made initial contact with the VMP. In the 4-MBC--treated male, the distal tips have penetrated the mesenchymal tissue and undergone later stages of branching morphogenesis. (*F*) Lateral and dorsal view of the UGS. Shape of the UGS (gray arrow) and bladder neck region of the urethra (black arrow) are changed in the 4-MBC--treated male.](ehp0116-000867f1){#f1-ehp0116-000867}

![Comparative volume analyses of individual and combined regions of the ASGs in PND1 males after prenatal exposure to various doses of UV filter compounds. Significant effects were observed only in the 7.0 mg/kg bw--treated males. Values shown are mean ± SE (*n* = 4 for all groups).\
\**p* \< 0.05, \*\**p* \< 0.01, ^\#^*p* \< 0.005, and ^\#\#^*p* \< 0.001 compared with control males.](ehp0116-000867f2){#f2-ehp0116-000867}

![Comparative volume analyses of specific regions of the developing prostate in PND1 males after prenatal exposure to various doses of UV filter compounds. Significant effects were observed only in the dorsal and ventral regions of the 7.0 mg/kg bw--treated males. Values shown are mean ± SE (*n* = 4 for all groups).\
\**p* \< 0.05, and \*\**p* \< 0.01 compared with control males.](ehp0116-000867f3){#f3-ehp0116-000867}

![Effects of prenatal exposure to UV filter compounds on prostate duct development in PND1 males. A significant increase in the number of developing ducts was observed in the combined dorsolateral prostate region (DLP). This increase was due specifically to an increase in the number of ducts in the caudal region of the dorsal prostate. Values shown are mean ± SE (*n* = 4 for all groups).\
\**p* \< 0.05 compared with control males.](ehp0116-000867f4){#f4-ehp0116-000867}

![Effect of prenatal exposure to 4-MBC (7.0 mg/kg bw) on VMP tissue volume in PND1 males. Values shown are mean ± SE (*n* = 4 for all groups).\
\**p* \< 0.05 compared with control males.](ehp0116-000867f5){#f5-ehp0116-000867}
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